Context: Persistence of hypogonadism is common in male patients with prolactinomas under dopamine agonist (DA) treatment. Conventional therapy with testosterone causes undesirable fluctuations in serum testosterone levels and inhibition of spermatogenesis. Objective: To evaluate the use of clomiphene as a treatment for persistent hypogonadism in males with prolactinomas. Design: Open label, single-arm, prospective trial. Patients: Fourteen adult hypogonadal males (testosterone !300 ng/dl and low/normal LH) with prolactinomas on DA, including seven with high prolactin (range: 29-1255 mg/l; median: 101 mg/l) despite maximal doses of DA. Intervention: Clomiphene (50 mg/day orally) for 12 weeks. Measures: Testosterone, estradiol, LH, FSH, and prolactin were measured before and 10 days, 4, 8, and 12 weeks after clomiphene. Erectile function, sperm analysis, body composition, and metabolic profiles were evaluated before and after clomiphene. Results: Ten patients (71%), five hyperprolactinemic and two normoprolactinemic, responded to clomiphene (testosterone O300 ng/dl). Testosterone levels increased from 201G22 to 457 G37 ng/dl, 436G52, and 440G47 ng/dl at 4, 8, and 12 weeks respectively (0.001!P!0.01). Estradiol increased significantly and peaked at 12 weeks. LH increased from 1.7G0.4 to 6.2G2.0 IU/l, 4.5G0.7, and 4.6G0.7 IU/l at 4, 8, and 12 weeks respectively (0.001!P!0.05). FSH levels increased in a similar fashion. Prolactin levels remained unchanged. Erectile function improved (P!0.05) and sperm motility increased (P!0.05) in all six patients with asthenospermia before clomiphene. Conclusions: Clomiphene restores normal testosterone levels and improves sperm motility in most male patients with prolactinomas and persistent hypogonadism under DA therapy. Recovery of gonadal function by clomiphene is independent of prolactin levels.
Introduction
Prolactinomas cause hypogonadotropic hypogonadism in both sexes. Medical treatment with dopamine agonists (DA) corrects hyperprolactinemia, decreases tumor size, and restores gonadal function in most patients (1) . However, 30-50% of male patients with prolactinomas under DA treatment, both with normal and with high prolactin levels, still remain hypogonadal (2) (3) (4) (5) (6) (7) . Persistent hypogonadism in these patients is treated with testosterone replacement, most often with intramuscular injections that require frequent applications and induce large fluctuations in serum testosterone levels with corresponding fluctuations in patients' energy, libido, sexual performance, and mood (8, 9) . In addition, testosterone replacement has an inhibitory effect on spermatogenesis and fertility, which is undesirable in patients wishing to have children (9) .
Clomiphene citrate is a well-known selective estrogen receptor modulator that increases gonadotropin secretion via hypothalamic-pituitary action. Clomiphene has already been extensively used in the evaluation of the gonadotropic axis and in the induction of ovulation. Clomiphene has also been shown to revert hypogonadotropic hypogonadism in several conditions like falciform anemia, uremia, alcohol, and steroid abuse, and to stimulate gonadotropin secretion in patients with sulpiride-induced hyperprolactinemia and gonadotropin suppression (10) (11) (12) (13) (14) . We conducted a prospective, open label clinical trial to evaluate the use of clomiphene as a treatment for persistent hypogonadism in male patients with prolactinomas under DA therapy (ClinicalTrials.gov number: NCT00697814).
Methods

Subjects
Sixteen out of 49 (33%) consecutive adult male patients with prolactinomas under DA therapy, seen between June 2004 and May 2005 at the Neuroendocrine Unit of the Endocrinology Division, Escola Paulista de Medicina -Universidade Federal de São Paulo, presented persistent hypogonadism and were considered to enter the protocol. Persistent hypogonadism was defined by total testosterone below 300 ng/dl (10.5 nmol/l), either normal/low LH and FSH levels after at least 6 months of DA therapy and normal serum prolactin levels or high serum prolactin levels under maximal DA doses (10 mg/day of bromocriptine or 3.5 mg/week of cabergoline for at least 2 months). Patients on testosterone replacement were evaluated after discontinuing testosterone for at least 2 months. All 16 patients had normal serum thyroxine (nine on levothyroxine) and four were on regular glucocorticoid replacement therapy. One patient with previous noncompliance to DA treatment was not included and another one left the study between 4 and 8 weeks and returned to testosterone replacement due to erectile dysfunction. All 14 patients who completed the study were analyzed.
Study design and protocol
This study was an interventional, open label, uncontrolled, single-arm, prospective trial of clomiphene citrate (Clomid, Medley, Campinas, SP, Brazil, kindly provided by Dr Enrico Repetto; 50 mg/day orally for 12 weeks) designed to assess its effects on serum testosterone levels in male patients with prolactinomas and persistent hypogonadism during DA therapy. As secondary aims, the effects of clomiphene on sexual function, sperm analysis, body composition, lipid and glucose metabolism, and quality of life (QoL) were also evaluated.
Physical examination, erectile function and QoL questionnaires, serum hormone measurements (testosterone, sex hormone-binding globulin (SHBG), estradiol, prolactin, LH, and FSH), prostate specific antigen (PSA), lipid (total, low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol, and triglycerides), serum glucose and insulin (before and after oral glucose), body composition, and sperm analysis (after 3 days of sexual abstinence) were all performed before and at the end of 12 weeks of clomiphene treatment. In addition, hormonal evaluations were performed at 10 days and at 4 and 8 weeks of treatment and after discontinuing clomiphene for 12 weeks.
The study protocol was approved by the institution's ethical committee and written informed consent was obtained from all participants.
Assays
Serum testosterone, SHBG, estradiol, prolactin, LH, FSH, insulin, and PSA were measured in fasting serum by automated immunochemoluminescent assays (ADVIA Centaur, Bayer). Free testosterone values were calculated from total testosterone and SHBG results using a fixed albumin level as previously described (15) . Glucose was measured in plasma using an enzymatic method (hexokinase II). Total cholesterol and triglycerides were measured in plasma by peroxidase colorimetric immunoenzymatic method. HDL cholesterol was measured in serum using immunoenzymatic method. LDL and VLDL were calculated by the Friedewald equation.
Body composition
Body composition (lean and fat mass and bone mineral content) was determined by dual-energy X-ray absorptiometry (QDR 2000-Plus, Hologic, Waltham, MA, USA), according to ICSD recommendations (16) .
Questionnaires
Erectile function was evaluated using a 15-question questionnaire (IIEF, international index of erectile function). QoL was evaluated using a 26-question questionnaire (WHOQOL-BREF, World Health Organization -QoL project). Both questionnaires have been previously validated in Portuguese (17, 18) .
Statistical analysis
Patients were classified as responders and nonresponders according to their testosterone levels during treatment (O300 ng/dl or 10.5 nmol/l) in at least two out of three measurements between 4 and 12 weeks of clomiphene. Considering baseline testosterone, a sample size of 14 patients has a 95% power to detect a normalization of mean testosterone. Statistical analyses were carried out using ANOVA or Friedman tests, according to data distribution, followed by Bonferroni or Dunn's post-tests respectively. Comparisons within the same group were performed by paired t-test or Wilcoxon signed-rank test according to data distribution. Comparisons between two independent groups were performed by unpaired t-test or Mann-Whitney test, as appropriate. Correlations between two variables were calculated by the Pearson coefficient (r). Statistical significance was set at P!0.05. Data are presented as mean GS.E.M. or as median when indicated. Data were analyzed using GraphPad Prism 4.03 and GraphPad StatMate 2 (La Jolla, CA, USA).
Results
Baseline characteristics
Among the 14 patients who concluded the study (age: 19-62 years; median: 39 years), 12 had macroadenomas and 2 had microadenomas at diagnosis; 12 patients were on bromocriptine and two were on cabergoline; seven patients had normal prolactin levels for at least 2 months before the study (range 2-18 months; median 4.5 months), and seven still had high prolactin levels (range: 29-1255 mg/l; median: 101 mg/l) on maximal doses of DA for at least 2 months before entering the study (range: 2-4 months). Testosterone had been withdrawn for at least 2 months (range: 2-24 months, median: 7 months) in all eight patients receiving testosterone replacement before entering the study. Six patients with macroprolactinomas had been previously submitted to pituitary surgery.
Effects of clomiphene on serum testosterone, estradiol, and gonadotropin levels
Ten patients (71%) were considered responders to clomiphene, including five with hyperprolactinemia (range: 29-345 mg/l, median: 101 mg/l); four patients (29%) were considered nonresponders, including two patients with hyperprolactinemia (44 and 1275 mg/l).
As shown in Fig. 1A , serum testosterone levels in responders to clomiphene increased from 201G22 ng/dl (7.03G0.8 nmol/l), at baseline, to 375G45 ng/dl (13.12G1.6 nmol/l) at 10 days (PO0.05), 457 G37 ng/dl (16G1.3 nmol/l) at 4 weeks (P!0.001), 440G47 ng/dl (15G1.7 nmol/l) at 8 weeks (P!0.001), and 435G38 ng/dl (15G1.3 nmol/l) at 12 weeks (P!0.001). Testosterone levels remained unchanged between 4 and 12 weeks of clomiphene (PZ0.71). Serum SHBG and free testosterone levels, evaluated at baseline and at 12 weeks, also increased significantly (P!0.05 and P!0.01 respectively), from 21G3.3 to 29G2.3 nmol/l and from 4.9G0.5 ng/dl (0.17G0.02 nmol/l) to 9.2G1.0 ng/dl (0.32 G0.03 nmol/l) respectively. At 12 weeks of clomiphene, free testosterone levels were within the normal range in all responders. Serum estradiol levels increased from 17.9G4.2 pg/ml (65.7G15.4 pmol/l) at baseline to 26.6G5.5 pg/ml (97.6G20.2 pmol/l) at 10 days (PO0.05), 31.7G7.6 pg/ml (116.4G27.9 pmol/l) at 4 weeks (PO0.05), 34.5G7.9 pg/ml (126.6 G29 pmol/l) at 8 weeks (P!0.05), and 37.0G7.1 pg/ml (135.8G26 pmol/l) at 12 weeks of clomiphene (P!0.01; Fig. 1B ).
As shown in Fig. 1C , serum LH levels increased from 1.7G0.4 to 4.0G0.7 IU/l at 10 days (P!0.05), 6.2G2.0 IU/l at 4 weeks (P!0.001), 4.5G0.7 IU/l at 8 weeks (P!0.01), and 4.6G0.7 IU/l at 12 weeks (P!0.01). Serum FSH levels increased from 3.7G1.1 to Figure 1 Response of serum testosterone, estradiol, LH, and FSH levels to clomiphene (50 mg/day) in male patients with prolactinomas and persistent hypogonadism under dopamine agonist therapy. Responders (R, solid squares) were defined as patients who showed serum testosterone levels O300 ng/dl during clomiphene. Responders showed significant increases in serum (A) testosterone, (B) estradiol, (C) LH, and (D) FSH as compared with baseline levels (*P!0.05, **P!0.01, ***P!0.001). After clomiphene was withdrawn, all hormones decreased to pretreatment levels. NZ10. Nonresponders (NR, open squares) did not reach testosterone levels O300 ng/dl during clomiphene and showed no significant changes in testosterone, estradiol, LH, and FSH levels as compared with baseline levels. To convert the values for testosterone to nmol/l, multiply by 0.0347. To convert the values for estradiol to pmol/l, multiply by 3.671. NZ4.
5.9G1.1 IU/l at 10 days (PO0.05), 7.9G3.5 IU/l at 4 weeks (P!0.05), 6.3G2.1 IU/l at 8 weeks (P!0.05), and 6.8G1.6 IU/l at 12 weeks (P!0.01; Fig. 1D ). Both LH and FSH levels remained unchanged between 4 and 12 weeks of clomiphene (PZ0.71 and PZ0.18 respectively). After 12 weeks of clomiphene withdrawn, total testosterone, LH, and FSH levels decreased significantly to pretreatment levels (214G25 ng/dl (7.5G0.9 nmol/l), 1.5G0.2 IU/l, and 4G1.1 IU/l respectively, P!0.01).
Among responders, hyperprolactinemic patients tended to have lower testosterone and LH levels as compared with normoprolactinemic patients before clomiphene (167G29 ng/dl (5.9G1 nmol/l) vs 237 G26 ng/dl (5.9G0.9 nmol/l), PZ0.056, and 1.0 G0.2 IU/l vs 2.5G0.6 IU/l, PZ0.09 respectively), but not after 4-12 weeks of clomiphene (PZ0.69 and PZ0.54 respectively).
To further analyze the influence of baseline prolactin status on the response to clomiphene, comparisons of testosterone levels at baseline and along clomiphene treatment between all hyperprolactinemic (nZ7) and all normoprolactinemic patients (nZ7) were performed, but failed to show any significant differences at any time point (0.3!P!0.9; unpaired t-test).
As shown in Table 1 , responders showed significantly higher total and free testosterone levels before treatment as compared with nonresponders, whereas LH and FSH levels tended to be higher, but no significant differences were observed in other characteristics. Both total and free testosterone levels at baseline significantly correlated (rZ0.81, PZ0.001, and rZ0.70, PZ0.005 respectively) with mean serum total testosterone levels during clomiphene treatment (Fig. 2) .
Effects of clomiphene on serum prolactin and PSA levels
In responders, serum prolactin levels showed no significant differences during clomiphene (PZ0.63), even when normoprolactinemic and hyperprolactinemic patients were analyzed in separate (PZ0.89 and PZ0.72 respectively), and no patient changed prolactin status. PSA levels also remained unchanged during treatment with clomiphene (PZ0.64).
Effects of clomiphene on erectile function and sperm analysis
As shown in Fig. 3 , erectile function scores (IIEF) increased significantly in responders, from 45G5 to 54G6 (P!0.05). In all six patients with asthenospermia before treatment, sperm motility increased from 33G3 to 46G3% after 12 weeks of clomiphene (P!0.05). Sperm count was normal in all but one of these patients and remained unchanged after clomiphene. In the four patients not analyzed, two had vasectomy, one had aspermia, and another one had normal sperm analysis before clomiphene.
Effects of clomiphene on body composition
In responders, a significant increase in bone mineral density was observed after clomiphene (1.138G0.03 vs 1.156G0.03 g/cm 2 , P!0.01), but no significant changes were observed in body mass index (31.1G1.4 vs 31.2G1.5 kg/m 2 , PZ0.91, t-test), fat-free mass (59G1.8 vs 60G1.9 kg, PZ0.19), or fat mass (28.5G2.7 vs 28.4G2.9 kg, PZ0.79). However, responders tended to gain and nonresponders tended to loose fat-free mass after clomiphene treatment (1.0 G0.7 vs K3.0G1.4 kg, PZ0.07). 
Metabolic effects
In responders, no significant variations in weight, abdominal circumference, blood pressure, fasting glucose, insulin, homeostasis model assessment-insulin resistance (HOMA-IR), total cholesterol, and cholesterol fractions were observed after 12 weeks of clomiphene treatment. Serum triglycerides decreased significantly (179G20 mg/dl (2G0.2 mmol/l) vs 128G20 mg/dl (1.5G0.2 mmol/l) at 12 weeks, PZ0.03). Serum glucose at 120 min after oral glucose tolerance test (OGTT) increased significantly at 12 weeks of clomiphene (103G5 mg/dl (5.7G0.3 mmol/l) vs 135G5 mg/dl (7.5G0.3 mmol/l), P!0.01), but no patient presented glycemia O200 mg/dl (highest value: 167 mg/dl (9.3 mmol/l)) at 120 min. Serum glucose at 120 min of OGTT before and after clomiphene correlated significantly (rZ0.87, PZ0.01).
Discussion
In this study, we have shown that chronic administration of clomiphene citrate was able to recover gonadal function in male patients with prolactinomas and persistent hypogonadotropic hypogonadism under DA treatment. Testosterone levels reached the normal range in nearly half of the responders as soon as 10 days after clomiphene was started, but only at 4 weeks had all responders reached normal testosterone levels which remained stable thereafter. Thus, a 4-week trial of clomiphene is able to identify most responders. Free testosterone levels also increased to the normal range in all responders, in spite of the significant increase in serum SHBG levels. When clomiphene was discontinued for 12 weeks, testosterone levels returned to the hypogonadal range in all responders, supporting both the therapeutic effect of clomiphene and the persistent nature of hypogonadism in those patients.
In responders, both erectile function and sperm motility also showed significant improvement during clomiphene treatment. Decreased motility is the most prevalent abnormality observed in sperm analysis of patients with untreated prolactinomas and may persist well beyond normalization of prolactin and testosterone levels with DAs (4). Improvement of sperm motility by clomiphene is likely to benefit fertility, in contrast with conventional testosterone replacement, which improves erectile function but usually decreases fertility (9) . As expected, estradiol levels also increased during clomiphene treatment, but only two of the ten responders showed slightly elevated estradiol levels (individual data not shown) and none developed gynecomastia. In these two patients, it is likely that lowering the dose of clomiphene could keep both testosterone and estradiol levels within the normal ranges.
At the end of the 12-week clomiphene treatment, responders also showed increased bone mineral density, reflecting a direct agonistic effect of clomiphene and/or of increased estradiol levels (19) . Although the expected changes in fat and fat-free masses were not significant during this period of time, responders tended to gain fat-free mass as compared with nonresponders. Serum triglycerides decreased, whereas fasting glucose and insulin levels and HOMA-IR were not affected by clomiphene treatment. A slight increase in serum glucose levels at 120 min after glucose was observed in responders, but no patient reached diagnostic criterion for diabetes mellitus. This finding is likely to reflect an antiestrogenic activity of clomiphene impairing glucose uptake. In male patients with inactivating mutations of estrogen receptor or aromatase, insulin resistance is increased and estradiol replacement improves insulin sensitivity in patients with aromatase deficiency (20, 21) .
The increase in testosterone levels during clomiphene treatment was brought about by its effects on gonadotropin secretion and not by decreasing prolactin levels as shown by increased LH and FSH and unchanged prolactin levels. In addition, clomiphene was equally effective in recovering gonadal function in both normoprolactinemic and hyperprolactinemic patients under DA treatment and no hyperprolactinemic patient became normoprolactinemic during clomiphene. Nevertheless, tamoxifen, another selective estrogen receptor modulator, has been reported to reduce prolactin secretion and tumor size in a few patients with resistant pituitary prolactinomas (22) .
Estrogen seems to be physiologically more relevant than testosterone in the negative feedback control of LH secretion in males. Accordingly, patients with inactivating mutations of the estrogen receptor or aromatase exhibit increased levels of gonadotropins and testosterone (20, 21) Also, circulating rather than locally generated estradiol (from testosterone aromatization) inhibits LH secretion in males by acting at both Figure 3 Effect of clomiphene (50 mg/day for 12 weeks) on erectile function and sperm motility in responders with asthenospermia before treatment. Sperm motility was analyzed in six out of ten responder patients after exclusion of two patients with vasectomy, one with aspermia, and one with normal sperm analysis.
hypothalamus and pituitary, but the major effect is through inhibition of hypothalamic GnRH release. Testosterone, on the other hand, exerts its own negative feedback on LH secretion through androgenic receptors at the hypothalamus (23) .
The ultimate in vivo effects of clomiphene, an estrogen receptor agonist/antagonist, are dependent on dose, target tissue, and endogenous estrogenic activity (24) . At low doses (25-50 mg/day), clomiphene is reportedly ineffective in prepubertal boys, but stimulates gonadotropin secretion in pubertal and adult males. At high doses (500 mg/day), clomiphene suppresses gonadotropin secretion even in normal adult males (25, 26) . In our study, a relatively low dose of clomiphene (50 mg/day) was able to increase and sustain serum gonadotropins and testosterone levels even in face of raising estradiol levels, which indicates an anti-estrogenic effect at the hypothalamus and/or pituitary. These results are completely in agreement with a major role of estrogen in the inhibitory feedback of gonadotropin secretion in males.
The gonadotropin-stimulating effect of clomiphene also indicates the presence of a critical inhibitory estrogen activity at the hypothalamus and/or pituitary in responders, which was effectively antagonized by clomiphene. However, no difference in serum estradiol was detected between responders and nonresponders, probably due to the insufficient sensitivity and accuracy of the estradiol assay. Notwithstanding, serum testosterone, the major source of estradiol in males, was significantly higher before treatment in responders as compared with nonresponders and strongly correlated with serum testosterone levels during clomiphene treatment. These data strongly suggest that the recovery of gonadal function by clomiphene in male patients with prolactinomas requires a critical hypothalamic-pituitary reserve.
In conclusion, clomiphene is an effective treatment for persistent hypogonadism in male patients with prolactinomas under DA treatment irrespective of serum prolactin levels. By restoring endogenous testosterone production and improving sperm motility, clomiphene is potentially beneficial in patients desiring to have children or exhibiting large fluctuations in serum testosterone levels under usual testosterone preparations.
Declaration of interest
